Intrathecal Dexmedetomidine to Decrease Postoperative Nausea and Vomiting and Shivering.
Status:
Completed
Trial end date:
2023-01-15
Target enrollment:
Participant gender:
Summary
Background: Highly selective α-2 agonist dexmedetomidine in increasingly used as an
intrathecal adjuvant for caesarean section performed under subarachnoid block.
Aim of the Study: The aim of the study is to determine whether low dose dexmedetomidine added
to local anesthetic for spinal anesthesia will attenuate perioperative nausea and vomiting
and shivering in lower segment caesarean section (LSCS) with minimal hemodynamic instability
or not.
Patients and Methods: Sixty parturients planned for elective CSs under spinal anesthesia were
enrolled in this prospective controlled study and randomly divided into two equal groups.
Spinal block was achieved with 10mg hyperbaric bupivacaine 0.5% plus 5µg dexmedetomidine
(group D) (dexmedetomidine group) or 0.2 ml normal saline (group C) (control group).
Hemodynamic parameters, incidence of nausea and vomiting and shivering were recorded.
Keywords: Dexmedetomidine, Cesarean Section, Bupivacaine, Spinal Anesthesia, Shivering, PONV